Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | MMP1 | P03956 | 3/20 | 0.55 |
| ▸ | MMP2 | P08253 | 3/20 | 0.55 |
| ▸ | MMP9 | P14780 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256239 | 1.00 | TTR (0.58) | TTRAPPPTPN1MAOAMAOB | |
| SCHEMBL2614742 | 1.00 | TTR (0.58) | TTRAPPPTPN1MAOAMAOB | |
| SCHEMBL31380287 | 1.00 | TTR (0.58) | TTRAPPPTPN1MAOAMAOB | |
| SCHEMBL69618 | 0.89 | TTR (0.66) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL2631340 | 0.84 | CA12 (0.66) | TTRAPPPTPN1MMP1MMP2 | |
| SCHEMBL3065424 | 0.84 | CA12 (0.66) | TTRAPPPTPN1MMP1MMP2 | |
| SCHEMBL30676338 | 0.84 | CA12 (0.66) | TTRAPPPTPN1MMP1MMP2 | |
| SCHEMBL1269502 | 0.83 | TTR (0.63) | TTRMAOAMAOBMMP1MMP2 | |
| SCHEMBL1269501 | 0.83 | TTR (0.63) | TTRMAOAMAOBMMP1MMP2 | |
| SCHEMBL2280675 | 0.83 | TTR (0.58) | TTRAPPPTPN1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059668-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2018-08-28 | — | — | US | disclosed |
| WO-2017079476-A1 | LSD1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170129857-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7517899-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1732887-B1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1732887-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1663201-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005097744-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005004861-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-01-20 | — | — | WO | disclosed |
| US-20040235830-A1 | Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-0590998-A1 | 1-Styryl-3-t-butyl-1,3-propanedione derivative and external preparation for skin using the same | SHISEIDO COMPANY LIMITED (JP) | 1994-04-06 | — | — | EP | disclosed |
| EP-0083228-B1 | PHARMACEUTICALLY ACTIVE PHENYLCARBOXYLIC ACID DERIVATIVES | ICI AMERICAS INC. (US) | 1985-05-15 | — | — | EP | disclosed |
| US-4499299-A | Pharmaceutically active phenylcarboxylic acid derivatives | ICI AMERICAS INC. (US) | 1985-02-12 | — | — | US | disclosed |
| EP-0083228-A1 | Pharmaceutically active phenylcarboxylic acid derivatives | ICI AMERICAS INC. (US) | 1983-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129857-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | TTR 4881/4885APP 3564/4885PTPN1 2830/4885 |
| US-20040235830-A1 | Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases | CYP46A1, REN, CYP11B2 | TTR 677/4885APP 746/4885PTPN1 4043/4885 |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | TTR 2182/4885APP 2841/4885PTPN1 3640/4885 |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | TTR 2182/4885APP 2841/4885PTPN1 3640/4885 |
| US-10059668-B2 | LSD1 inhibitors | KDM1B, KDM1A, KDM3A | TTR 4881/4885APP 3564/4885PTPN1 2830/4885 |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | TTR 2182/4885APP 2841/4885PTPN1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.